The announcement of a comprehensive plan to resolve all current and future claims related to ovarian cancer from cosmetic talc litigation could positively impact Johnson & Johnson's stock price in the short term. This move is likely to be viewed favorably by investors as it aims to reduce the legal uncertainties and financial liabilities that have been overhanging the company. By addressing these issues head-on, J&J is taking a proactive step to mitigate risks associated with the litigation, which could lead to improved investor confidence and stock performance.